Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Capital Medical University · China-Japan Friendship Hospital · +24 more institutions
Indexed incrossrefdatacitepubmed
Abstract
No abstract available for this paper.
Citation impact
3,659
total citations
- FWCI
- 86.79
- Percentile
- 100%
- References
- 30
Citations per year
Authors
46- YWYeming WangCorresponding
Capital Medical University, China-Japan Friendship Hospital, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Tongji Hospital, Huazhong University of Science and Technology
- DZDingyu Zhang
- GDGuanhua Du
Chinese Academy of Medical Sciences & Peking Union Medical College
- RDRonghui Du
Wuhan Pulmonary Hospital
- JZJianping Zhao
Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
Topics
Keywords
- Coronavirus disease 2019 (COVID-19)
- Medicine
- Placebo
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- 2019-20 coronavirus outbreak
- Double blind
- Betacoronavirus
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BABill and Melinda Gates FoundationAwards: 200907, OPP1209135
- GSGilead SciencesAward: COVID-19
- WTWellcome TrustAwards: 215091, 215091/Z/18/Z
- NSNew Sunshine Charity Foundation
- NINational Institute for Health and Care ResearchAward: 200907
- DODepartment of Health and Social Care
- DFDepartment for International DevelopmentAward: 215091/Z/18/Z
- NHNational Health Research InstitutesAward: 2015-08-001
- CAChinese Academy of Medical SciencesAward: 2020HY320001
- NINational Institutes of HealthAward: COVID-19
- NKNational Key Research and Development Program of ChinaAwards: SARS-CoV-2, 2018YFC1200102
- BSBeijing Science and Technology Planning ProjectAward: Z19110700660000
- NKNational Key New Drug Creation and Manufacturing Program, Ministry of Science and TechnologyAward: 2020ZX09201012